Archives

Defense Unicorns Raises $136 Million Series B to Build the Software Backbone of the Department of War

BainCapital

Reaching a $1B valuation underscores Defense Unicorns’ role as modern foundational infrastructure for secure software delivery across critical military platforms.

SAN ANTONIO – Jan. 13, 2026 – Today, Defense Unicorns, the leader in airgap software delivery for national security mission systems, announced the completion of a $136 million Series B financing round led by Bain Capital. The investment brings the company to unicorn status with a valuation exceeding $1 billion, driven by the company’s rapid and profitable growth. The company has seen a 300% increase in adoption year-over-year in military systems.

The Department of War is prioritizing modernization and speed, and Defense Unicorns’ platform addresses a critical infrastructure challenge by enabling secure, rapid software updates across disconnected environments from submarines, ships, and aircraft to forward operating bases. Warfighters often operate in conditions where connectivity is limited or nonexistent, and the ability to deploy software updates securely and instantly is now essential to mission success. Unicorn Delivery Service (UDS) bridges high security requirements while supporting partners and allies with modern software solutions essential for next-generation national security capabilities.

“Defense Unicorns gives our nation a wartime software advantage,” said Dr. Rob Slaughter, CEO of Defense Unicorns. “The U.S. has significant commercial software advantages, but the systems we go to war with are typically outdated. At Defense Unicorns, we make software a strategic deterrent by making it easy to deploy and operate software in any mission environment,” continued Dr. Slaughter.

The funding round was led by Bain Capital’s Tech Opportunities fund, the growth technology platform of Bain Capital. With participation from Ansa Capital, Sapphire Ventures, Valor Equity Partners, AVP, Uncorrelated Ventures, and the former Director of the Central Intelligence Agency, David H. Petraeus.

“We are thrilled to support Defense Unicorns as it works to ensure that U.S. service members have access to the most advanced, secure, and rapidly deployable software possible. Defense Unicorns plays a vital role in helping the military modernize mission systems, enabling capabilities that directly improve readiness, resilience, and operational advantage in the field,” said Dewey Awad, a Partner at Bain Capital Tech Opportunities. “We believe Defense Unicorns is building foundational infrastructure for modern defense,” added Zach Berger, a Managing Director at Bain Capital Tech Opportunities. “The company combines unmatched technical expertise with a deep understanding of how the military operates, and that combination is critical to delivering real, measurable impact for service members who rely on software in high-stakes environments.”

Demand for secure software delivery continues to rise. Marco DeMeireles, Co-Founder and Managing Partner at Ansa Capital, stated, “We’ve been proud to partner with Defense Unicorns since the Series A, and our continued investment reflects the conviction we’ve built watching the team execute against an incredibly complex and mission-critical problem. What Rob and the team have built is foundational infrastructure for modern defense, and this next chapter only reinforces the scale of impact ahead.”

The new capital will enable Defense Unicorns to further scale and integrate open-source and commercial dual-use technology throughout the U.S. military and allied forces. To address the most critical modernization needs in defense, the company plans to advance product development across the following strategic products:

  • UDS: A secure, portable, airgap-native runtime platform, purpose-built to solve DOW-specific software delivery challenges. UDS makes deploying and updating software on military systems fast and easy, with essential tools for packaging, deploying, monitoring, and sustaining mission applications.
  • UDS Registry: The first software registry of its kind to offer the speed, reliability, and mission-critical performance required by military systems operating in the most extreme environments. UDS Registry gives the U.S. and our allies an American-maintained solution that secures our software supply chain and maintains trust and reliability across the software development lifecycle.
  • UDS Army: A new approach to accelerate the continuous delivery of secure, mission-ready software to soldiers. UDS Army gives commercial software vendors a faster, simpler path to bring their capabilities to Army missions by combining secure DevSecOps pipelines with pre-authorized cloud environments.

“Before UDS, there was no open, secure, and airgap-native modern software delivery capability for warfighters. More than just a piece of software, UDS is an entire open ecosystem of tools and technologies purpose-built to securely bring capabilities to the field faster. I’m grateful for the incredible teams at Defense Unicorns that continue to evolve UDS to bring even more technical advantage to our nation’s heroes,” concluded Co-Founder and CTO Jeff McCoy.

About Defense Unicorns
Defense Unicorns is a veteran-owned defense technology company founded in 2021 by Rob Slaughter, Jeff McCoy, and Andrew Greene to make software a strategic deterrent for the U.S. Department of War. The company builds open-source, airgap-native technologies that enable the secure development, delivery, and sustainment of mission software across cloud, on-premises, and tactical edge environments. Defense Unicorns’ technology is trusted by the operators of some of the most critical systems in the world, including the U.S. Navy, Army, Air Force, and Space Force.
Learn more at https://defenseunicorns.com.

About Bain Capital 
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit &Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850employees, and approximately $185 billion in assets under management. Bain Capital’s Tech Opportunities business (baincapitaltechopportunities.com) aims to help growing technology companies reach their full potential. We focus on companies in large, growing end markets with innovative or disruptive technology where we believe we can support transformational growth. Our dedicated, tenured team has deep experience supporting growing technology businesses—bringing together differentiated backgrounds in private and public equity investing as well as technology operating roles. We invest behind fundamental long-term tailwinds as technology penetrates across industries, creating a large and growing number of investment opportunities. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

Media Contacts

 

Eddie de Sciora

Categories: News

Tags:

Bain Capital Real Estate Closes on $5 Billion in New Capital, Expanding Scale Across High-Conviction Strategies

BainCapital

Firm completes fundraising for Real Estate Fund III, with $3.4 billion in commitments

BOSTON – January 13, 2026 – Bain Capital today announced the close of more than $5 billion in new capital across its real estate strategies, including the completion of fundraising for Bain Capital Real Estate Fund III (“Fund III” or the “Fund”), with approximately $3.4 billion in total commitments. Fund III received significant support from a diverse group of new and existing limited partners globally, and includes $300 million from Bain Capital employees and alumni, underscoring the firm’s long-standing commitment to ensuring alignment with its investors.

The final close of Fund III follows Bain Capital Real Estate’s recent $1.6 billion capital raise alongside 11North Partners, which will invest through their co-owned, open-air, necessity-based retail operating platform. Together, these raises, along with additional co-investments, represent more than $5 billion of investible capital across Bain Capital Real Estate strategies, enhancing the firm’s ability to invest selectively and at scale across its highest-conviction themes. These successful capital formation efforts represent a significant increase over the $3 billion in total commitments raised by Bain Capital Real Estate Fund II.

Fund III continues to reflect Bain Capital Real Estate’s research-driven, thematic investment approach, providing curated exposure to sectors that complement traditional real estate portfolios. The team invests behind long-dated secular trends, partners with experienced operators through dedicated platforms, and maintains a disciplined, flexible approach as market conditions, pricing, and liquidity evolve. Within that framework, Fund III is focused primarily on value-add opportunities in demand-driven, supply-constrained, and often hard-to-access sectors where active ownership and operational improvement can drive accelerated performance. Core areas of focus include urban infill industrial, open-air retail, leisure and hospitality, medical outpatient buildings, for-rent townhomes, senior housing, marinas and storage facilities, and digital real estate assets.

“We are grateful for the continued support of our limited partners and their conviction in our strategy and growing platform, which has delivered strong performance through one of the most challenging real estate cycles in decades,” said Ryan Cotton, Partner and Head of Bain Capital Real Estate. “Our thematic focus, underpinned by rigorous analysis and collaboration across Bain Capital’s platform, combined with disciplined selectivity and active management, positions us well to invest successfully across cycles. Looking ahead, we believe we are competitively advantaged to capitalize on long-term secular trends driven by changes in how people live, work, and spend, and we remain committed to building enduring partnerships with investors and operators who share our long-term view.”

The Bain Capital Real Estate team has built a differentiated sourcing edge, including the ability to originate opportunities off market by leveraging Bain Capital’s platform advantages, thematic insights, and experience executing complex transactions. Further, the team has strengthened its capabilities through the recent establishment of real estate-dedicated Asset Management, Debt Capital Markets, and Investor Relations functions. Notable recent investments include the acquisition of a leading private golf club platform in partnership with Bain Capital Private Equity; the acquisition of a portfolio of 10 open-air retail centers across Florida and South Carolina, most of which are anchored by Publix; the acquisition of an industrial portfolio primarily located in Northern New Jersey; the acquisition of Boathouse Marine Center, a dry-stack marina in Pompano Beach, Florida; and the acquisition of an approximately 122,000 square-foot medical outpatient facility in the Washington, DC metropolitan area.

About Bain Capital Real Estate
Bain Capital Real Estate pursues investments in often difficult-to-access sectors underpinned by enduring secular trends that drive long-term demand growth for real estate assets and services. The Bain Capital Real Estate team has invested and committed over $10.7 billion of equity across multiple sectors as of September 30, 2025. Bain Capital Real Estate focuses on assets where the team applies its deep industry expertise to accelerate impact and drive operational improvements. Bain Capital Real Estate’s strategy aligns with the value-added investment approach that Bain Capital pioneered and leverages the firm’s global platform and significant experience across asset classes to further bolster its insights and sourcing capabilities. Bain Capital is one of the world’s leading private investment firms, with approximately $215 billion of assets under management. For more information, visit https://www.baincapitalrealestate.com.

 

Categories: News

Tags:

Alt Goes Mainstream: Inside Infrastructure Investing

Stonepeak

Cyrus Gentry, CEO of SP+ INFRA, joined Michael Sidgmore of the Alt Goes Mainstream podcast at one of Stonepeak’s newest data center assets to break down what makes infrastructure assets durable – hard asset backing, mission-critical services, high barriers to entry, and inflation-linked pricing power – and to share insights on the development of Stonepeak+, the firm’s dedicated wealth platform. Listen in for a thoughtful discussion on today’s infrastructure investing landscape and a practical framework for where the asset class fits in an investment portfolio.

 

Categories: News

Tags:

Jens Brenninkmeyer appointed CEO of Bregal Investments

Bregal Investments

Zug, Switzerland; Tuesday, 13 January 2026 – COFRA Holding AG (“COFRA”) announces the appointment of Jens Brenninkmeyer as Chief Executive Officer of Bregal Investments, effective 1 February 2026.

Jens joined Bregal Investments in 2023 where, as Chief Strategy Officer, he led a review of the firm’s platform strategy while overseeing new deal activity and portfolio management across six strategies. He began his investing career at Goldman Sachs before leading the fintech investing strategy at Sixth Street.

“Jens has successfully managed Bregal Investments and developed a new platform strategy. He is a leader who cares deeply about creating strong returns for partners, investors and communities. With his strategic foresight, I am confident Jens is well-positioned to lead Bregal’s diversification into new investment strategies, recruit exceptional teams and help to grow the Bregal platform.”

Boudewijn Beerkens

CEO – COFRA Holding AG

“I’m pleased to step into the CEO role at a key moment in Bregal’s development. We have an ambitious platform strategy, with defined priorities for diversification and growth, and I look forward to working closely with our talented Managing Partners and their teams to deliver for each of our stakeholders.”

Jens Brenninkmeyer

Incoming CEO – Bregal Investments

Jens holds an MBA from Harvard Business School and a Bachelor’s in Business Administration from Georgetown University.

Jens’ appointment as CEO of Bregal Investments is subject to regulatory approval.

 

Press
Kieran Toohey
COFRA Holding
press@cofraholding.com | +31 612 976 813

About COFRA Holding 

COFRA Holding AG is a privately held group, headquartered in Switzerland, with operations in Europe, the Americas and Asia. COFRA has a diverse portfolio of investment businesses in private equity (Bregal Investments), real estate (Redevco) and asset management (Anthos Fund & Asset Management). Businesses and investments are also held in retail, clean energy and sustainable food. Through business, COFRA strives to be a force for good in the world – a mission that has characterised the Brenninkmeijer family owners’ activities for six generations, since the founding of C&A in 1841. For more information, see cofraholding.com or follow us on LinkedIn

About Bregal

Bregal is a global investment platform that partners with and builds exceptional private markets teams. Bregal provides capital, expertise, and infrastructure across the manager’s life cycle – from incubation and seeding to primaries, co-investments, and secondaries. Managing over €19 billion in assets across its direct and external manager-focused strategies, Bregal invests in private equity, growth equity, impact, and private credit. As part of COFRA Holding, a sixth-generation family enterprise, Bregal combines long-term partnership, institutional discipline, and purpose-driven stewardship to create sustainable value for its partners, investors, and communities. Headquartered in London and New York, the Bregal platform employs more than 300 professionals across nine global offices. For more information, see bregal.com

Categories: People

WindRose Health Investors Makes Investment in Avalon Healthcare Solutions

Franciso Partners

New York, NY, January 12, 2026 – WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed an investment in Avalon Healthcare Solutions (“Avalon” or the “Company”), a platform that integrates laboratory science and data to power real-time, lab-driven insights on behalf of health plan clients. Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, has also made an additional investment in the company. Avalon helps to ensure the appropriate use of routine and genetic lab tests and manages a national network of independent test providers.

WindRose’s investment and deep experience scaling tech-enabled payer services solutions will enable Avalon to accelerate its growth trajectory, invest in novel product offerings and further develop its next-generation technology platform. Avalon is uniquely positioned to address the complex and evolving needs of payers with its proprietary technology that automatically reviews and enforces lab test claims against client-adopted, clinically-derived policies. Avalon’s management team, headed by CEO Bill Kerr, will continue to lead the Company in its next phase of growth.

“We are grateful for Francisco Partners’ continued support and are excited to partner with WindRose and begin this next chapter,” said Mr. Kerr. “Francisco Partners has enabled us to grow and scale Avalon to where it is today, and we believe WindRose is a perfect additional partner to support the Company’s growth strategy of delivering an end-to-end lab benefit management platform. With the help of WindRose’s investment and strategic involvement, Avalon will continue to drive meaningful efficiencies on behalf of its health plan clients while also focusing on investing in innovation and building out its suite of capabilities.”

“Avalon has built a leadership position as a preferred partner to health plans that seek operational efficiencies while managing increasingly complex lab benefits. Avalon’s purpose-built lab insights platform uniquely combines lab benefits management, clinical science, and analytics to deliver value to its clients. We are thrilled to partner with Bill and the team to scale the business and continue to support product innovation,” said David Pontius, Partner at WindRose.

“Avalon has evolved into a differentiated, mission-critical partner for health plans by combining deep clinical expertise with a highly scalable technology platform,” said Ezra Perlman, Co-President of Francisco Partners. “We are excited to continue supporting Bill and the Avalon team as they invest in new product capabilities and drive meaningful impact for payers navigating an increasingly complex diagnostics landscape.”

William Blair acted as financial advisor to Avalon. McDermott Will & Schulte LLP acted as legal advisor to WindRose, Kirkland and Ellis acted as legal advisor to Francisco Partners and Davis Polk & Wardwell LLP acted as legal advisor to Avalon.

About WindRose Health Investors

New York City-based WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. With approximately $7 billion under management, WindRose invests in companies throughout the United States. For more information, please email us at info@windrose.com.

About Francisco Partners

Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 25 years ago, Francisco Partners has invested in over 500 technology companies, making it one of the most active and longstanding investors in the technology industry. With over $50 billion in capital raised to date, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.

About Avalon Healthcare Solutions

Headquartered in Tampa, Florida, Avalon is a healthcare technology company focused on managing the appropriate use of thousands of routine and genetic diagnostic laboratory tests on behalf of health plan clients. Avalon’s library of evidence-based lab policies is actively managed by a team of scientists and encoded into its proprietary platform to help payers reduce avoidable costs and improve clinical outcomes. For more information, please visit www.avalonhcs.com.

Contact:
Lambert by LLYC
Caroline Luz
cluz@lambert.com
203-570-6462

Categories: News

Tags:

EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases

No Comments
EQT Life Science

EQT Life Sciences x Kinaset Therapeutics

  • EQT Life Sciences invests in U.S.-based Kinaset Therapeutics – a clinical-stage biopharma company developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases
  • Proceeds from the oversubscribed USD 103 million Series B round to help advance frevecitinib – a single-capsule dry powder inhaler delivering therapeutic lung concentrations, with the potential to treat the broad asthma population
  • EQT Life Sciences’ Daniela Begolo to join Kinaset Therapeutics’ Board of Directors

EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the “Company”), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases.

The investment was made as part of Kinaset’s oversubscribed USD 103 million Series B financing, led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life Sciences, Vivo, Schroders, Willett Advisors, Pictet, and Sixty Degree Capital, as well as existing investors Atlas Venture, 5AM Ventures, and Gimv.

Asthma affects millions of patients worldwide, yet a significant proportion remains inadequately controlled on existing therapies. Today’s biologic treatments mainly help patients with certain types of inflammation, leaving many with severe asthma without effective options. This has created a clear unmet need for broadly effective, safe, and inhaled anti-inflammatory therapies that can address the full spectrum of asthma disease.

Kinaset Therapeutics’s Series B will be used to help advance frevecitinib, a novel inhaled dry powder in development for patients with asthma that remains inadequately controlled by standard of care inhaled maintenance therapies. Frevecitinib is an inhaled pan-JAK inhibitor – an immune-modulating medication – designed to deliver therapeutic concentrations directly to the lungs via a single-capsule dry powder inhaler, while minimizing systemic exposure.
Daniela Begolo, Managing Director at EQT Life Sciences, who will join Kinaset’s Board of Directors, said: “Kinaset is taking a highly differentiated approach to asthma by pairing validated JAK biology with an inhaled delivery designed to maximize lung exposure while minimizing systemic risk. Backed by a strong and experienced management team, Kinaset has the potential to address a broad asthma population, including patients not well served by current therapies, making frevecitinib a particularly compelling program to advance into later-stage development.”

Robert Clarke, CEO of Kinaset Therapeutics, said: “Since day one, our goal has been to establish a best-in-class therapeutic for the treatment of severe inflammatory respiratory diseases. Critically, and unlike the majority of existing therapeutics, frevecitinib can provide benefit to all patients with severe asthma including those with a non-eosinophilic phenotype who continue to suffer from an absence of safe and effective therapies. This financing marks a significant milestone for Kinaset to execute our vision of advancing frevecitinib through a Phase 2 dose-ranging clinical study in severe asthma and potentially beyond. The participation of leading life science investors underscores both the strength of our team and the critical unmet need we aim to address.”

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.

More information: www.eqtgroup.com/private-capital/eqt-life-sciences

About Kinaset Therapeutics, Inc.
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company.

See more information at the Company’s website 

Categories: News

Tags:

EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics

EQT Life Science

EQT Life Sciences

  • EQT Life Sciences to exit portfolio company Vivasure Medical in sale to Haemonetics
  • Vivasure’s PerQseal® Elite system uses a special bioabsorbable patch to seal large access sites in arteries or veins from the inside
  • EQT supported Vivasure from its Series C investment in 2016 through clinical development and toward market approval

EQT Life Sciences is pleased to announce that the LSP Health Economics Fund has exited Vivasure Medical Limited (“Vivasure” or the “Company”), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure, through a sale to Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes.

Vivasure’s PerQseal® Elite system uses a special bioabsorbable patch to seal large access sites in arteries or veins from the inside, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the PerQseal Elite system and received CE Mark approval in Europe for both arterial and venous use.

EQT Life Sciences (formerly LSP) first invested in Vivasure in 2016 from the LSP Health Economics Fund, leading the Company’s Series C funding round. From 2016 to 2025, EQT was represented on the Company’s board by Partner Anne Portwich, providing active strategic support as Vivasure advanced its products through clinical studies and towards market approval.

The acquisition includes an upfront cash payment of EUR 100 million, and up to an additional EUR 85 million in contingent consideration based on sales growth and the achievement of certain other milestones. The LSP Health Economics Fund is entitled to a portion of this amount, corresponding to its minority shareholding in the Company.

Anne Portwich, Partner at EQT Life Sciences and former board member at Vivasure, said: “It has been a great honour to serve on the board of Vivasure. Supporting companies with products that make better treatments available to patients and improve the quality of care lies at the core of our health economics strategy. This also further underscores the importance of venture capital in bringing innovation to patients.”

Andrew Glass, Chief Executive Officer of Vivasure Medical Limited, said: “We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians, employees, board members, investors and government bodies who supported Vivasure’s mission. Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide.”

Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics, concluded: “Acquiring Vivasure expands Haemonetics’ complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures. With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals.”

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients

More info: www.eqtgroup.com/private-capital/eqt-life-sciences

About Vivasure Medical Limited
Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility. PerQseal and PerQseal Elite are not available for sale in the United States.

For more information, please visit www.vivasuremedical.com

About Haemonetics
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.

To learn more about Haemonetics, visit www.haemonetics.com

Categories: News

Tags:

EQT Real Estate acquires a portfolio of four high-quality logistics assets in Northern Italy

eqt

EQT Real Estate acquires a portfolio of four high-quality logistics assets in Northern Italy

  • EQT Real Estate has acquired a logistics portfolio totalling approximately 107,000 square metres, located in key Italian markets including Milan, Bologna and Verona
  • Assets offer long-term income with significant value creation opportunities, supported by Grade A technical specifications and strong sustainability credentials
  • Transaction strengthens EQT Real Estate’s exposure to the Italian logistics market, one of Europe’s most attractive and supply-constrained markets

EQT is pleased to announce that the EQT Exeter Europe Logistics Core-Plus Fund II (“EQT Real Estate”), has acquired a high-quality logistics portfolio comprising four assets (the “Properties”) located in the key Northern Italian submarkets of Milan, Bologna and Verona. The assets will be acquired by Kryalos SGR S.p.A on behalf of EQT Real Estate.

The Properties, totalling approximately 107,712 sqm and which are fully let to a strong, diversified tenant base, comprise modern, institutional-quality logistics assets. The portfolio benefits from excellent connectivity to core distribution locations via key motorways, including the A1, A4 and A22, providing access to major population centres and a catchment area of more than 20 million inhabitants. 

The transaction further enhances EQT Real Estate’s exposure to the Italian logistics market, which continues to benefit from attractive structural trends and favorable supply-demand dynamics shaping market conditions. The acquisition reflects EQT Real Estate’s confidence in the Italian logistics sector’s long-term prospects and its ability to generate long-term value through active asset management and sustainability-led initiatives.

Greg Vinson, Partner at EQT Real Estate, said: “The transaction fits perfectly within our Core Plus strategy’s objective to acquire highly reversionary, modern logistics assets that offer long-term lease stability, stable income and significant value creation opportunities. As the Italian logistics market remains resilient, driven by demand for Grade A and sustainability-compliant warehouses, we are thrilled to be expanding our exposure and further drive value in the Properties that are well-connected to some of Italy’s fastest-growing cities”.

EQT Real Estate was advised by Legance (tax and legal), Howden (insurance), Arcadis (technical).

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Real Estate
EQT is a purpose-driven global investment organization with EUR 267 billion in total assets under management (EUR 139 billion in fee-generating assets under management) as of 30 September 2025, divided into two business segments: Private Capital and Real Assets. EQT supports its global portfolio companies and assets in achieving sustainable growth, operational excellence, and market leadership. Within EQT’s Real Assets segment, EQT Real Estate acquires, develops, leases, and manages logistics and residential properties in the Americas, Europe, and Asia. EQT Real Estate manages about $58 billion in GAV, owns and operates over 2,000 properties and 400 million square feet, with over 400 experienced professionals across 50 locations globally.

More info: www.eqtgroup.com
Follow EQT Real Estate on LinkedIn

About Kryalos
With €13.8 billion of AuM and a team of 125 professionals, Kryalos is one of the most active players in the Italian real estate market. The company offers transaction management, real estate and credit fund management, development and advisory services and is a partner of Italian and international leaders. Further information on www.kryalossgr.com

Categories: News

Tags:

Platinum Equity Invests in Norton Packaging

Platinum

LOS ANGELES (January 9, 2026) – Platinum Equity announced today a significant investment in Norton Packaging, a provider of plastic pails and packaging solutions.

Founded in 1901 and headquartered in Hayward, Calif., Norton is a provider of high-performance rigid packaging solutions for a range of categories including paints and coatings, chemicals and cleansers, food products, lubricants and other applications.

“For more than a century, Norton has demonstrated a commitment to quality, consistency, and deep customer relationships. We believe that foundation, combined with the company’s technical expertise and service‑oriented culture, makes Norton an exceptional platform for growth. ”

Jacob Kotzubei, Co-President, Platinum Equity

“We have great respect for the Norton family and the business they’ve built over multiple generations,” said Platinum Equity Co‑President Jacob Kotzubei. “For more than a century, Norton has demonstrated a commitment to quality, consistency, and deep customer relationships. We believe that foundation, combined with the company’s technical expertise and service‑oriented culture, makes Norton an exceptional platform for growth. We see meaningful opportunities to invest in the business, support continued innovation, and help the company reach even greater scale.”

Norton Packaging CEO Greg Norton and the Norton family retained a significant interest in the business and Mr. Norton will continue to lead the company going forward.

“We are excited about the prospect of partnering with Platinum Equity,” said Mr. Norton. “Our family has always believed in doing things the right way. That means putting customers first, investing in our people and staying committed to manufacturing excellence. Platinum’s track record in the packaging sector and its experience helping family‑led businesses grow gives us confidence that this is the right partner for the next chapter in Norton’s evolution.”

Platinum Equity has invested in numerous packaging businesses. The firm’s current portfolio includes Growscape, a North American manufacturer and supplier of horticultural containers and decorative, functional products for the lawn and garden market. Platinum Equity previously owned BWAY, a manufacturer of rigid metal and plastic containers used to package industrial, bulk food and retail goods.

“Norton has built an impressive business with a loyal customer base, and we believe the company is well positioned for both organic and strategic growth,” said Platinum Equity Managing Director Nick Fries. “We see significant opportunities to enhance its operations, expand capacity where needed, and pursue add‑on acquisitions that can broaden the company’s capabilities and geographic reach. We’re looking forward to working with Greg and the Norton team to help accelerate their long‑term growth plans.”

Financial terms were not disclosed.

Stifel served as financial advisor and Gibson, Dunn & Crutcher LLP served as legal counsel to Platinum Equity on the Norton acquisition. Perella Weinberg Partners LP served as financial advisor and Donahue Fitzgerald LLP served as legal counsel to Norton Packaging.

About Platinum Equity

Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with approximately $50 billion of assets under management and a portfolio of approximately 60 operating companies that serve customers around the world. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 30 years Platinum Equity has completed more than 500 acquisitions.

Categories: News

Tags:

EQT Foundation invests in Biographica, an agritech startup at the intersection of AI and crop genetics

eqt

EQT Foundation invests in Biographica, a UK-based company using machine learning to accelerate gene discovery for crop improvement.

Biographica’s platform enables faster, more precise identification of genetic traits that can boost yield, reduce pesticide use, and improve climate resilience.

The investment will support commercial rollout and lab expansion to build a new generation of climate-ready crops.

Biographica is developing an advanced machine learning platform to decode the genetic architecture of crops, cutting down the time, cost, and failure rate of bringing new agricultural traits to market. Traditional pipelines can take over a decade and often miss key gene targets. Biographica’s approach identifies promising edit targets earlier and with higher accuracy, enabling partners to develop novel traits that reduce input costs and adapt to changing climate conditions.

EQT Foundation has invested in Biographica as part of the company’s seed round. The investment follows growing commercial traction with leading seed companies including BASF | Nunhems and Cibus, both of which have progressed from pilot projects to commercial contracts tied to development milestones.

Biographica is initially focused on licensing trait discoveries to seed companies through success-based commercial structures. The company’s foundational model has already been used to identify high-priority gene targets for disease resistance and yield traits, with two partners now progressing targets into validation pipelines. A core focus for the next phase is narrowing in on trait areas with strong demand signals and clear unit economics to drive co-development and licensing deals.

With a founding team experienced in biological ML, plant science, and bioinformatics, Biographica’s platform is designed to work across a wide range of crops. Recent internal benchmarks show significantly higher gene discovery accuracy compared to conventional approaches, helping reduce the time and cost of delivering edited traits.

The company has also opened its first lab at Rothamsted Research and is expanding its in-house capability to generate validation data, inform model development, and support licensing efforts.

Cecy Price, CEO and Co-founder, Biographica: “We’ve seen AI reshape pharma, turning trial-and-error pipelines into learnable biological systems – and it works. We’re bringing that same discipline to crops. Our partnerships leading seed companies show the industry is ready for AI-first approaches to trait discovery, to bring high-value crop varieties to market in seasons, not decades.”

Contact

EQT Press Office

press@eqtpartners.com+46 8 506 55 334

About EQT

EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of more than three decades of developing companies across multiple geographies, sectors and strategies. EQT has investment strategies covering all phases of a business’ development, from start-up to maturity. EQT has €‌​​267​‌ billion in total assets under management (€139​‌ billion in fee-generating assets under management) as of 30 September 2025, within two business segments – Private Capital and Real Assets.

With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.

The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in more than 25 countries across Europe, Asia and the Americas and has more than 1,900 employees.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram

About EQT Foundation

EQT Foundation is a philanthropic organization and long-term shareholder of the global investment organization EQT, founded by partners at EQT. The Foundation supports scientists and entrepreneurs bringing breakthrough solutions from lab to market, combining EQT’s expertise with catalytic investments and grants. With a focus on supporting scientific progress in underfunded areas of climate and health, the Foundation provides a learning platform for EQT employees to develop and work collaboratively across the globe, while engaging in philanthropy and making a positive impact.

LinkedIn

About Biographica

Biographica is a London-based agricultural biotechnology company applying breakthroughs from AI-driven drug discovery to design the next generation of crop traits. The company was founded in 2022 by Cecily Price and Dominic Hall, who combine deep expertise in genetics, AI, and computational biology. They are joined by a team of leading scientists and engineers at the intersection of biology and AI, in London and at Rothamsted Research, and advised by seed industry leaders across R&D partnerships and licensing. Biographica is already working with several of the world’s top seed companies, including BASF | Nunhems.

Categories: News